K011697

## JUN 2 7 2001

## 510(k) Summary of Safety & Effectiveness

This 510(k) Summary of Safety and Effectiveness for the EBI® XFIX® Access™ Pelvic Fixator is provided as required per Section 513(I)(3) of the Food, Drug and Cosmetic Act.

1. Submitter: EBI, L.P.

100 Interpace Parkway

Parsippany, NJ 07054

Contact Person: Jon Caparotta, RAC

Telephone: (973) 299-9022

Date prepared: May 31, 2001

2. Proprietary Name:

EBI® XFIX® Access™ Pelvic Fixator

**Common Name:** 

External Fixation Device

**Classification Names:** 

Single Multiple Component Metallic Bone

Fixation Appliances and Accessories, 21 CFR

888,3030.

3. Predicate or legally marketed devices that are substantially equivalent:

■ EBI® XFIX® DFS® System – Electro-Biology, Inc.

4. Description of the device: The EBI® XFIX® Access™ Pelvic Fixator has not changed the Indications for Use or fundamental scientific technology of the previous cleared system. The system consists of external fixation components and implantable bone screws. The EBI® XFIX® Access™ Pelvic Fixator is utilized in the following manner: bone screws are inserted through the patient's skin and soft tissue and into the bone. The fixator frame of the EBI® XFIX® Access™ Pelvic Fixator is attached to the shanks of the bone screws. This submission is for the use of a carbon fiber bar that will replace the current titanium bar.

- 5. Intended Use: The EBI® XFIX® Access™ Pelvic Fixator and EBI® XFIX® DFS® System are unilateral external fixation devices intended for use in the treatment of bone conditions including leg lengthening, osteotomies, arthrodesis, fracture fixation, and other bone conditions amenable to treatment by use of the external fixation modality.
- 6. Materials: The components of the system are manufactured from materials such as Ti-6A1-4V ELI, Aluminum, Stainless Steel, and Carbon Fiber.

7. Comparison of the technological characteristics of the device to predicate devices: There are no significant differences between the EBI® XFIX® Access™ Pelvic Fixator m and other currently marketed external fixation systems. It is substantially equivalent\* to the predicate devices in regards to intended use, materials and function. Testing comparing the modifications to the previous system demonstrated that the device complies with applicable standards and meets all of its functional requirements.

<sup>\*</sup>Any statement made in conjunction with this submission regarding a determination of substantial equivalence to any other product is intended only to relate to whether the product can be lawfully marketed without pre-market approval or reclassification and is not intended to be interpreted as an admission or any other type of evidence in patent infringement litigation. [Establishment Registration and Premarket Notification Procedures, Final Regulation, Preamble, August 23, 1977, FR 42520 (Docket No. 76N-0355.)]



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

## JUN 2 7 2001

Mr. Jon Caparotta, RAC Manager, Regulatory Affairs EBI, L.P. 100 Interpace Parkway Parsippany, New Jersey 07054-1079

Re: K011697

Trade Name: EBI XFIX Access Pelvic Fixator

Regulation Number: 888.3030

Regulatory Class: II Product Codes: KTT Dated: May 31, 2001 Received: June 1, 2001

Dear Mr. Caparotta:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general control provisions of the Act. The general control provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597, or at its Internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and

Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

## STATEMENT OF INDICATIONS FOR USE

Page1 of1		
510(k) Number (if known):	K01169	7
Device Name: EBI® XFIX®	Access TM Pelvi	c Fixator
Indications For Use:		
The EBI® XFIX® Access™	Pelvic Fixator an	nd EBI® XFIX® DFS® System are unilateral
external fixation devices inte	nded for use in th	ne treatment of bone conditions including leg
lengthening, osteotomies, art	hrodesis, fracture	fixation, and other bone conditions amenable to
treatment by use of the extern		
(PLEASE DO NOT WRITE NEEDED)	BELOW THIS L	INE-CONTINUE ON ANOTHER PAGE IF
Concurren	ce of CDRH, Off	ice of Device Evaluation (ODE)
Prescription Use_X_	OR	Over-The-Counter Use
(Per 21 CFR 801.109)		
		(Optional Format 1-2-96)

(Division Sign-Off)
Division of General, Restorative and Neurological Devices

510(k) Number KOHG 97